Captain T Cell develops first-in-class, efficacy-enhanced T cell therapies against solid tumors that are not addressed by existing treatments. Captain T Cell generates next-generation TCR-T cells with enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors. In addition, the company has established a novel allogeneic platform to enable off-the-shelf treatments of solid tumors. Captain T Cell is based in Schoenefeld/Berlin, Germany, and backed by leading European investors i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H. Captain T Cell was founded by a dedicated team of immuno-oncology experts using technology developed at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Company Details
- Employees
- 12
- Address
- Willy-Brandt Platz, Schönefeld,brandenburg 12529,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.captaintcell.com
- HQ
- Schönefeld, Brandenburg
Captain T Cell Questions
Captain T Cell's website is http://www.captaintcell.com
Captain T Cell's LinkedIn profile is https://de.linkedin.com/company/captain-t-cell
Captain T Cell has
12 employees.
View email and phone details for 12
employees at Captain T Cell.
Captain T Cell's industry is
Biotechnology Research
Captain T Cell's top competitors are
Immuneadvice Gmbh,
Lucid Genomics,
Pan Cancer T,
Neutrogen Therapeutics,
Myopax,
Engimmune Therapeutics,
T-Knife Therapeutics,
Alaunos Therapeutics,
Medigene Ag,
Hhc Medical.
Captain T Cell's categories are Biotechnology Research
